Cosmetic regional conjunctivectomy with postoperative mitomycin C application with or without bevacizumab injection

Seonheui Lee, Jeongae Go, Soolienah Rhiu, R. Doyle Stulting, Min Lee, Sunyoung Jang, Sangmoo Lee, Hyung Joon Kim, Eui Sang Chung, Sooyoung Kim, Kyoung Yul Seo

Research output: Contribution to journalArticlepeer-review

16 Citations (Scopus)

Abstract

Purpose: To evaluate the complications of cosmetic wide conjunctivectomy and postoperative topical mitomycin C application with or without bevacizumab injection. Design: Cross-sectional cohort study. Methods: Medical records of 1713 consecutive subjects who received cosmetic wide conjunctivectomy plus postoperative topical mitomycin C by a single surgeon at a single center with or without bevacizumab injection from November 2007 to May 2010 were reviewed. A telephone interview was conducted with 557 of the subjects who could be contacted and agreed to participate in the study. Complications, recurrences, and patient satisfaction were the main outcome measures. Results: A total of 1713 consecutive patients underwent cosmetic wide conjunctivectomy to treat conjunctival hyperemia. Ocular diagnoses in the medical records at the time of surgery included hyperemia (8.8%), pterygium (14.0%), dry eye (3.5%), pinguecula (1.5%), and conjunctival disorder (23.3%). For the remaining 48.9% of subjects, the diagnosis was not mentioned, or the surgical procedure was for cosmetic purposes. Patients were followed for a mean of 10.9 months (range, 0-30.3 months). The overall complication rate was 82.9%, of which 55.6% were considered severe (fibrovascular conjunctival tissue proliferation, 43.8%; scleral thinning, 4.4%; scleral thinning with calcified plaques, 6.2%; intraocular pressure elevation, 13.1%; diplopia, 3.6%; and recurrence of hyperemic conjunctiva, 28.1%). Conclusions: Cosmetic wide conjunctivectomy plus postoperative topical mitomycin C with or without bevacizumab injection has a high rate of complications and reoperations.

Original languageEnglish
Pages (from-to)616-622.e3
JournalAmerican Journal of Ophthalmology
Volume156
Issue number3
DOIs
Publication statusPublished - 2013 Sep

Bibliographical note

Funding Information:
All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest and none were reported. Publication of this article was supported by a faculty research grant from The Ministry of Health and Welfare for 2011 ( HTA-2011-7 ), Seoul, South Korea and Yonsei University College of Medicine for 2010 ( 6-2010-0045 ), Seoul, South Korea. Contributions of authors: involved in design (Se.L., S.R., H.J.K., E.S.C., S.K., K.Y.S.) and conduct of the study (Se.L., S.R., K.Y.S.); data collection (Se.L., J.G., M.L., S.J., Sa.L.), analysis (Se.L., S.R., S.K., K.Y.S.), and interpretation (Se.L., S.R., K.Y.S.); and preparation, review, and approval of the manuscript (Se.L., S.R., R.D.S., K.Y.S.).

All Science Journal Classification (ASJC) codes

  • Ophthalmology

Fingerprint Dive into the research topics of 'Cosmetic regional conjunctivectomy with postoperative mitomycin C application with or without bevacizumab injection'. Together they form a unique fingerprint.

Cite this